A Phase 2 interventional study of GR1802 injection and Placebo in Allergic Rhinitis, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Active, not recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.
Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 13th largest by enrollment of the 67 interventional ones that give a count, is one of 22 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 5 of the 33 other live ones, and was the 47th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 5–18
Pengfei Qiu · Sites in China
Ages 18–75
Inmunotek S.L. · Sites in China, Argentina, Portugal and 1 more country
Ages 12–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 11 · Phase 4 9
First in 2006; this study’s year is marked. 22 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 93 across the 67 interventional studies, 270 across the 15 observational. Of the 40 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genrix (Shanghai) Biopharmaceutical Co., Ltd., one of the names counted as Chongqing Genrix Biopharmaceutical Co., Ltd. Under that name alone:
Genrix (Shanghai) Biopharmaceutical Co., Ltd. is the lead sponsor of 28 studies on the registry; 17 are open to participants now.
Chongqing Genrix Biopharmaceutical Co., Ltd has 1 study filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
8 of the studies in Rhinitis, Allergic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07784491Zhongshan Torch Development Zone People's HospitalSphenopalatine Ganglion Acupuncture for Allergic Rhinitis | 2026-12-31 |
| NCT07079748LanZhou UniversityStudy of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms | 2026-12-31 |
| NCT07453771The Affiliated Hospital of Qingdao UniversitySafety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 82 studies in Rhinitis, Allergic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: GR1802 injection
Biological: GR1802 injection
Biological: Placebo
Recombinant fully human anti-IL4Rα monoclonal antibody drug.
Placebo
Change from Baseline in rTNSS( reflective total nasal symptom scores)
TNSS is the sum of the four symptom scores of runny nose, nasal congestion, nasal itching, and sneezing, with each symptom scoring from 0 to 3. The total score is 12, the higher the score, the worse the symptoms.
Time frame: Over 2 weeks
Change from Baseline in rTOSS( reflective total ocular symptom scores)
TOSS is the sum of symptom scores of eye itching/foreign body sensation/redness and tearing, with each symptom scoring from 0 to 3. The total score is 6, the higher the score, the worse the symptoms.
Time frame: Over 2、4 weeks
Change from Baseline in rTNSS
TNSS is the sum of the four symptom scores of runny nose, nasal congestion, nasal itching, and sneezing, with each symptom scoring from 0 to 3. The total score is 12, the higher the score, the worse the symptoms.
Time frame: Over 4 weeks
Mean change from baseline in iTNSS(instantaneous total nasal symptom scores)
TNSS is the sum of the four symptom scores of runny nose, nasal congestion, nasal itching, and sneezing, with each symptom scoring from 0 to 3. The total score is 12, the higher the score, the worse the symptoms.
Time frame: week 2、4
Mean change from baseline in iTOSS(instantaneous total ocular symptom scores)
TOSS is the sum of symptom scores of eye itching/foreign body sensation/redness and tearing, with each symptom scoring from 0 to 3. The total score is 6, the higher the score, the worse the symptoms.
Time frame: week 2、4
Change from baseline in VAS(Visual Analog Scale) score
Patients marked the score corresponding to the severity of the current overall AR symptoms by drawing a line on a 0-10 cm scale,the higher the score, the worse the symptoms.
Time frame: week2、4
Change from baseline in RQLQ(Rhinoconjunctivitis Quality of Life Questionnaire) scores
The RQLQ is used to measure the problems that adults with rhinoconjunctivitis experience in their daily lives. It has 28 questions in 7 domains. The total score is the sum of the 7 domain scores, with higher scores being associated with poorer quality of life.
Time frame: week2、4
Adverse events (AEs)
Incidence of AEs.
Time frame: up to 12 weeks
Immunogenicity characteristics
Positive rate of ADA(anti-drug antibody) testing
Time frame: up to 12 weeks
Started Mar 2024 (actual). Primary completion is estimated for May 2025, 14 months after the start.
Of 31 phase 2 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 14 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telikibart
Genrix (Shanghai) Biopharmaceutical Co., Ltd. →